Consistency Analysis of Imaging and Histological Diagnosis of Non-alcoholic Fatty Liver Disease
1. Department of Hepatology, Nanjing Hospital Affiliated to Nanjing University of Chinese Medicine/Nanjing Second Hospital, Nanjing 210003, China 2. Department of Pathology, Nanjing Hospital Affiliated to Nanjing University of Chinese Medicine/Nanjing Second Hospital, Nanjing 210003, China 3. Department of General Surgery, Nanjing Hospital Affiliated to Nanjing University of Chinese Medicine/Nanjing Second Hospital, Nanjing 210003, China
HU Yifan,CHEN Miaoyang,XIONG Qingfang, et al. Consistency Analysis of Imaging and Histological Diagnosis of Non-alcoholic Fatty Liver Disease[J]. Chinese General Practice, 2024, 27(28): 3546-3551. DOI: 10.12114/j.issn.1007-9572.2023.0539.
胡一帆,陈妙洋,熊清芳等. 影像学和组织学诊断胆石症合并非酒精性脂肪性肝病的一致性研究[J]. 中国全科医学, 2024, 27(28): 3546-3551. DOI: 10.12114/j.issn.1007-9572.2023.0539.
COTTERT G,RINELLAM. Nonalcoholic fatty liver disease 2020:the state of the disease[J]. Gastroenterology,2020,158(7):1851-1864. DOI:10.1053/j.gastro.2020.01.052.
[2]
BROWNG T,KLEINERD E. Histopathology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis[J]. Metabolism,2016,65(8):1080-1086. DOI:10.1016/j.metabol.2015.11.008.
[3]
BEDOSSAP,PATELK. Biopsy and noninvasive methods to assess progression of nonalcoholic fatty liver disease[J]. Gastroenterology,2016,150(8):1811-1822.e4. DOI:10.1053/j.gastro.2016.03.008.
NASCIMBENIF,BEDOSSAP,FEDCHUKL,et al. Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease[J]. J Hepatol,2020,72(5):828-838. DOI:10.1016/j.jhep.2019.12.008.
[7]
CHENL L,YANGH Q,LIH T,et al. Insights into modifiable risk factors of cholelithiasis:a mendelian randomization study[J]. Hepatology,2022,75(4):785-796. DOI:10.1002/hep.32183.
[8]
KOLLERT,KOLLEROVAJ,HLAVATYT,et al. Cholelithiasis and markers of nonalcoholic fatty liver disease in patients with metabolic risk factors[J]. Scand J Gastroenterol,2012,47(2):197-203. DOI:10.3109/00365521.2011.643481.
[9]
RUHLC E,EVERHARTJ E. Relationship of non-alcoholic fatty liver disease with cholecystectomy in the US population[J]. Am J Gastroenterol,2013,108(6):952-958. DOI:10.1038/ajg.2013.70.
[10]
WANGX J,MALHIH. Nonalcoholic fatty liver disease[J]. Ann Intern Med,2018,169(9):ITC65. DOI:10.7326/aitc201811060.
FRACANZANIA L,VALENTIL,RUSSELLOM,et al. Gallstone disease is associated with more severe liver damage in patients with non-alcoholic fatty liver disease[J]. PLoS One,2012,7(7):e41183. DOI:10.1371/journal.pone.0041183.
[13]
CHOUDHARYN S,SARAFN,DHAMPALWARS,et al. Nonalcoholic fatty liver disease in living donor liver transplant recipients:a histology-based study[J]. J Clin Exp Hepatol,2022,12(5):1328-1332. DOI:10.1016/j.jceh.2022.04.012.
[14]
RINELLAM E. Nonalcoholic fatty liver disease:a systematic review[J]. JAMA,2015,313(22):2263-2273. DOI:10.1001/jama.2015.5370.
DI CIAULAA,WANGD Q H,PORTINCASAP. An update on the pathogenesis of cholesterol gallstone disease[J]. Curr Opin Gastroenterol,2018,34(2):71-80. DOI:10.1097/MOG.0000000000000423.
[17]
MEMAJP,JORNAYVAZF R. Non-alcoholic fatty liver disease in type 1 diabetes:prevalence and pathophysiology[J]. Front Endocrinol,2022,13:1031633. DOI:10.3389/fendo.2022.1031633.
[18]
STEFANN,CUSIK. A global view of the interplay between non-alcoholic fatty liver disease and diabetes[J]. Lancet Diabetes Endocrinol,2022,10(4):284-296.